Related Experiment Video
Updated: Jan 2, 2026

08:29
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
Published on: February 1, 2019
10.5K
Nanomedicines Lost in Translation
Keegan Guidolin1,2,3, Gang Zheng2,4,3
1Department of Surgery , University of Toronto , Toronto M5G 1L7 , Canada.
ACS Nano
|December 5, 2019
Summary
Nanomedicines face challenges in clinical translation. Understanding "clinical multifunctionality" and "diagonal translation" can help biomedical engineers improve nanomedicine development and adoption.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Drug Delivery
Background:
- Nanomedicines often fail to achieve clinical relevance and successful translation.
- Key features of nanomedicines are frequently overlooked by biomedical engineers.
- Traditional multifunctionality at the nanoscale differs from clinical applications.
Purpose of the Study:
- To discuss reasons for the difficulty in nanomedicine clinical translation.
- To highlight overlooked features of nanomedicines for biomedical engineers.
- To introduce and emphasize the concept of clinical multifunctionality.
Main Methods:
- Perspective-based discussion of nanomedicine translation challenges.
- Analysis of emergent clinical multifunctionality in translated nanomedicines.
- Description of the "diagonal translation" phenomenon.
Main Results:
- Clinical multifunctionality, distinct from nanoscale multifunctionality, is crucial for nanomedicine success.
- Examples demonstrate emergent clinical multifunctionality upon translation.
- Diagonal translation occurs when nanomedicines solve unintended clinical problems.
Conclusions:
- Biomedical engineers can leverage clinical multifunctionality and diagonal translation to enhance nanomedicine development.
- Recognizing these phenomena can bridge the gap between nanomedicine design and clinical utility.
- A shift in perspective towards clinical application is vital for nanomedicine translation.
More Related Videos
Related Concept Videos
Translation
154.8K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
154.8K
Translation
17.4K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
Translation Produces the Building Blocks of Life
Proteins are...
17.4K
Leaky Scanning
5.6K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.6K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
123
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
123
Initiation of Translation
38.2K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
38.2K
Improving Translational Accuracy
14.0K
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
14.0K

